3,4-二氢-2H-苯并[1,4]噁嗪-2-羧酸乙酯 | 22244-22-0

• 物质功能分类: 化学试剂 - 有机试剂 - 酯类
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并恶嗪类
• 中文名称: 3,4-二氢-2H-苯并[1,4]噁嗪-2-羧酸乙酯
• 中文别名: 3,4-二氢-2H-1,4-苯并恶嗪-2-羧酸乙酯
• 英文名称: ethyl 3,4-dihydro-2H-benzo [b][1,4]oxazine-2-carboxylate
• 英文别名: ethyl 3,4-dihydro-2H-1,4-benzoxazine-2-carboxylate；2(R,S)-ethoxycarbonyl-3,4-dihydro-2H-1,4-benzoxazine
• CAS: 22244-22-0
• 化学式: C₁₁H₁₃NO₃
• 分子量: 207.229
• InChiKey: FGYXHLIMQKWPIL-UHFFFAOYSA-N

物化性质

• 沸点：
  131-133 °C
• 密度：
  1.167±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  47.6
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2934999090
• 危险性防范说明：
  P273
• 危险性描述：
  H302,H411
• 储存条件：
  -20°C，避光，惰性气体

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: Ethyl 3,4-dihydro-2H-1,4-benzoxazine-2-carboxylate
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H302: Harmful if swallowed
H411: Toxic to aquatic life with long lasting effects
P273: Avoid release to the environment

---

Section 3. Composition/information on ingredients.
Ingredient name: Ethyl 3,4-dihydro-2H-1,4-benzoxazine-2-carboxylate
CAS number: 22244-22-0

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C11H13NO3
Molecular weight: 207.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3,4-二氢-2H-苯并[1,4]噁嗪-2-羧酸乙酯 在 氢氧化钾 、 potassium carbonate 、 对甲苯磺酸 、 lithium diisopropyl amide 作用下， 以 四氢呋喃 、 甲醇 、 丙酮 为溶剂， 反应 41.0h， 生成 methyl 2,4-dimethyl-3,4-dihydro-2H-1,4-benzoxazine-2-carboxylate
  参考文献：
  名称：

  新型2-（4,5-二氢-1H-咪唑-2-基）-3,4-二氢-2H-1,4-苯并恶嗪衍生物的合成和生物学评估。

  摘要：

  已经开发了2-（4,5-二氢-1H-咪唑-2-基）-3,4-二氢-2H-1,4-苯并恶嗪衍生物和在苯并恶嗪部分的氮原子上具有稠合的附加环的三环类似物。制备并评估其作为潜在的降压药的心血管作用。咪唑啉环是通过相应的乙酯与乙二胺反应生​​成的。评估咪唑啉结合位点（IBS）I（1）和I（2）以及α（1）和α（2）肾上腺素能受体的亲和力，以及对平均动脉血压（MAP）和心率（HR）的影响自发性高血压大鼠。除少数例外，MAP上活性最高的化合物是对IBS和alpha（2）受体具有高亲和力的化合物。在这些化合物中，化合物4h是最有趣的，现在与它的对映异构体一起，

  DOI：

  10.1021/jm021050c
• 作为产物：
  描述：

  ethyl 3,4-dihydro-2H-benzo [b][1,4]oxazine-3-carboxylate 生成 3,4-二氢-2H-苯并[1,4]噁嗪-2-羧酸乙酯
  参考文献：
  名称：

  2,9-diamino- and 2-amino-8-carbamoyl-4-hydroxy-alkanoic acid amide

  摘要：

  公式I的化合物##STR1##中，其中R.sub.1是芳基氨基，N-芳基-N-(较低烷氧基-较低烷基)-氨基，N-芳基-N-芳基-较低烷基-氨基或通过环碳原子连接的杂环基，X是羰基或亚甲基基团，R.sub.2和R.sub.3彼此独立地是氢或较低烷基，或者与它们连接的碳原子一起是环烷基亚甲基基团，R.sub.4是氢，较低烷基，较低烷酰基或较低烷氧羰基，R.sub.5是羟基，较低烷酰氧基或较低烷氧羰氧基，R.sub.6是氢，较低烷基，较低烯基，较低炔基，环烷基，环烷基-较低烷基，芳基-较低烷基或杂环芳基-较低烷基，在杂环芳基环中有5到7个环原子，R.sub.7是氢或较低烷基，或者R.sub.6和R.sub.7与它们连接的碳原子一起是环烷基亚甲基基团，R.sub.8表示脂肪，环脂肪-脂肪或杂环脂肪基团，它们的盐可用作治疗高血压药物的活性成分。

  公开号：

  US05719141A1

文献信息

• MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR
  申请人：Binch Hayley

  公开号：US20100168094A1

  公开（公告）日：2010-07-01

  The present invention relates to modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator, compositions thereof, and methods therewith. The present invention also relates to methods of treating diseases using such CFTR modulators.

  本发明涉及调节ATP结合盒（“ABC”）转运蛋白或其片段的调节剂，包括囊性纤维化跨膜传导调节蛋白，以及相关的组合物和方法。本发明还涉及利用这些CFTR调节剂治疗疾病的方法。
• [EN] 5-AMINO-4-CARBAMOYL-PYRAZOLE COMPOUNDS AS SELECTIVE AND IRREVERSIBLE T790M OVER WT-EGFR KINASE INHIBITORS AND USE THEREOF<br/>[FR] COMPOSÉS 5-AMINO-4-CARBAMOYL-PYRAZOLE UTILISÉS COMME INHIBITEURS SÉLECTIFS ET IRRÉVERSIBLES DE T790M SUR LA KINASE WT-EGFR, ET LEUR UTILISATION
  申请人：BEIGENE LTD

  公开号：WO2016008411A1

  公开（公告）日：2016-01-21

  Disclosed are compounds of Formula (I), pharmaceutical compositions comprising the same, processes for the preparation thereof, and the use thereof.

  公开了公式(I)的化合物，包括含有该化合物的药物组合物，制备该化合物的方法以及该化合物的用途。
• Heterocyclic compounds
  申请人：Adir et Compagnie

  公开号：US06057317A1

  公开（公告）日：2000-05-02

  Compound of formula (I): ##STR1## wherein: Y, R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7, R.sub.8 and n are as defined in the description, and medicinal products containing the same which are useful as imidazoline receptor ligands.

  公式(I)的化合物：##STR1## 其中：Y、R₁、R₂、R₃、R₄、R₅、R₆、R₇、R₈和n如描述中定义，以及含有相同化合物的药物，这些药物作为咪唑啉受体配体是有用的。
• Discovery of a new class of potent, selective, and orally active prostaglandin D2 receptor antagonists
  作者：Kazuhiko Torisu、Kaoru Kobayashi、Maki Iwahashi、Yoshihiko Nakai、Takahiro Onoda、Toshihiko Nagase、Isamu Sugimoto、Yutaka Okada、Ryoji Matsumoto、Fumio Nanbu、Shuichi Ohuchida、Hisao Nakai、Masaaki Toda

  DOI：10.1016/j.bmc.2004.07.048

  日期：2004.10

  acetic acid analogs is presented since these compounds represent a new class of potent, selective, and orally active prostaglandin D2 (PGD2) receptor antagonists. Most of these compounds exhibit strong PGD2 receptor binding and PGD2 receptor antagonism in cAMP formation assays. When given orally, these new antagonists dramatically suppress allergic inflammatory responses, such as the PGD2-induced or

  提出了发现一系列N-（对烷氧基）苯甲酰基-2-甲基吲哚-4-乙酸类似物的过程，因为这些化合物代表了一类新的强效，选择性和口服活性前列腺素D2（PGD2）受体拮抗剂。这些化合物大多数在cAMP形成分析中表现出较强的PGD2受体结合和PGD2受体拮抗作用。口服时，这些新的拮抗剂可显着抑制过敏性炎症反应，例如PGD2诱导或OVA诱导的血管通透性增加。还讨论了结构活动关系（SAR）数据。
• 5-phenylpyrrolo-1,4-benzoxazine and 5-phenylpyrrolo-1,4-benzothiazine
  申请人：Kali-Chemie Pharma GmbH

  公开号：US05474988A1

  公开（公告）日：1995-12-12

  Pharmacologically active compounds of formula I ##STR1## which can be substituted in the phenyl rings and in which R.sup.1 denotes hydrogen or lower alkyl, R.sup.2 denotes hydrogen or lower alkyl, Y denotes oxygen or sulfur n represents an integer from 1 to 3 Z represents a bond, a CO group or a CH.dbd. group, Q denotes nitrogen or the CH group and R.sup.7, if Q denotes nitrogen, represents an optionally substituted pyridyl or phenyl radical or, if Q denotes the CH group, represents the N-methyl-N-(4-oxo-3H-pyrimidin-2-yl)amino group, and their acid addition salts and processes and intermediates for their preparation.

  化学式I的药理活性化合物，可以在苯环中进行取代，其中R.sup.1代表氢或较低的烷基，R.sup.2代表氢或较低的烷基，Y代表氧或硫，n表示1到3之间的整数，Z代表键合，CO基团或CH基团，Q代表氮或CH基团，R.sup.7如果Q代表氮，则代表可选择取代的吡啶基或苯基，如果Q代表CH基团，则代表N-甲基-N-(4-氧代-3H-嘧啶-2-基)氨基基团，以及它们的盐酸盐和用于其制备的过程和中间体。